New Haven drug developer Achillion Pharmaceuticals Inc. was awarded $2 million in eight federal grants to fund ongoing research into treatments for blood-borne ailments.
Achillion says the funding is through a program in the federal government’s affordable health care package to reimburse eligible participants for research that serves unmet medical needs and that has the potential to create and sustain jobs.
Achillion is in clinical testing of treatments for hepatitis C and HIV.
